PegIntron Versus IntronA in CMAJCC Stage II (EADO 2001/CMII Trial) (EADO)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00221702|
Recruitment Status : Completed
First Posted : September 22, 2005
Last Update Posted : October 13, 2010
|Condition or disease||Intervention/treatment||Phase|
|Melanoma Neoplasm Metastasis||Drug: PegIntron Drug: intron A||Phase 3|
Study design and primary objective
This is an European multicenter, open label, prospective randomized phase III trial evaluating the efficacy of long-term maintenance therapy of two therapy options, IntronA for 18 months versus PegIntron for 36 months, administered in an adjuvant setting after the local excision of an intermediate risk cutaneous melanoma.
Intermediate risk melanoma is defined by the following criteria: (1) a tumor thickness >= 1,5mm and (2) the absence of regional nodal macrometastases, as assessed either by clinical examination or, if sentinel lymph node biopsy (SLNB) or elective node dissection (ELND) are performed, by the absence of macroscopic evidence of disease. Patients with evidence of nodal micrometastasis by SLNB or ELND are eligible. The choice of performing sentinel node dissection will be left to the decision of each center, on condition to concern all consecutive patients and that all surgical procedures are completed before randomization of the patients . The centers have to inform their respective national study center if they perform SLNB or ELND and also if they change their surgical procedure.
- Arm A : PegIntron 100 mcg SC/week for 36 months
- Arm B : IntronA 3miu TIWW SC for 18 months
The primary endpoint of the study will be the time to any recurrence (local recurrence, satellite or in transit metastasis, regional node metastasis or distant metastasis) or death, whatever the cause. The primary comparison between the two arms will use the 5-year disease-free survival time. Secondary endpoints are time to distant metastasis , overall survival, toxicity and quality of life.
Therapy with either PegIntron or IntronA will continue as scheduled unless there is evidence of disease progression (whether local or distant recurrence), severe toxicity, or the subject requests that therapy be discontinued. All patients will be followed for disease-free-survival and overall survival until the end of the trial.
Sample size and analysis
The calculated sample size is 1190 patients to be enrolled over a 5 years period; this sample size is inclusive of an expected lost to follow up not more than 10% during the course of the trial. The randomization procedure will be stratified according to centers and to sentinel node biopsy. The primary analysis will be performed under the intent to treat principle.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||898 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Randomized, Multicenter Phase III Trial Comparing Adjuvant Treatment With PegIntron Over 36 Months Versus Reference Treatment With IntronA Over 18 Months in Cutaneous Melanoma Patients AJCC Stage II (>=1.5 mm Clinically Node Negative)|
|Study Start Date :||June 2003|
|Actual Primary Completion Date :||October 2010|
|Actual Study Completion Date :||October 2010|
Peg Intron 100 mcg SC/week for 36 months
100 mcg SC/week for 36 months
Active Comparator: B
Intron A 3 X 3 MIU, weekly, sc, for 18 months
Drug: intron A
3mui TIWW SC for 18 months
- disease-free survival time [ Time Frame: 5-year ]
- time to distant metastasis [ Time Frame: the time from the inclusion to the first documentation of any distant metastasis ]
- overall survival [ Time Frame: the time from the inclusion to the date of death regardless of the specific cause ]
- toxicity [ Time Frame: for 36 months ]
- quality of life [ Time Frame: 36 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00221702
|Marseille, France, 13274|
|Principal Investigator:||Jean - Jacques GROB, Professor||University Hospital, Marseille|
|Study Chair:||Geneviève Chêne, Professor||University Hospital, Bordeaux|